Free Newsletter
Immune Design recruits former Elan exec
Former Elan president Carlos Paya has signed on as Immune Design's new CEO. The Seattle-based vaccine developer, which was founded in 2008, is developing therapeutic vaccines for the treatment of infectious and malignant disease. Xconomy reports that the company has already raised $50 million in venture capital and inked a partnership deal with AstraZeneca's Medimmune. Report
More stories about Immune Design
Comments
Post a comment
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: